Deferred Tax Assets, Valuation Allowance of Apellis Pharmaceuticals, Inc. from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Apellis Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
Apellis Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $734,816,000, a 1.6% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$734,816,000	+$11,233,000	+1.6%	31 Dec 2025	10-K	24 Feb 2026	2025	FY
Q4 2024	$723,583,000	-$29,805,000	-4%	31 Dec 2024	10-K	24 Feb 2026	2025	FY
Q4 2023	$753,388,000	+$116,868,000	+18%	31 Dec 2023	10-K	28 Feb 2025	2024	FY
Q4 2022	$636,520,000	+$97,735,000	+18%	31 Dec 2022	10-K/A	29 Feb 2024	2023	FY
Q4 2021	$538,785,000	+$141,673,000	+36%	31 Dec 2021	10-K	21 Feb 2023	2022	FY
Q4 2020	$397,112,000	+$240,177,000	+153%	31 Dec 2020	10-K	28 Feb 2022	2021	FY
Q4 2019	$156,935,000	+$77,573,123	+98%	31 Dec 2019	10-K	25 Feb 2021	2020	FY
Q4 2018	$79,361,877	+$38,156,506	+93%	31 Dec 2018	10-K	27 Feb 2020	2019	FY
Q4 2017	$41,205,371	+$11,176,292	+37%	31 Dec 2017	10-K	26 Feb 2019	2018	FY
Q4 2016	$30,029,079			31 Dec 2016	10-K	19 Mar 2018	2017	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.